ID
33098
Description
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella
Keywords
Versions (1)
- 11/27/18 11/27/18 -
Copyright Holder
GSK group of companies
Uploaded on
November 27, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020
Diary Card: Unsolicited Symptoms (All Groups) - Dose 2
- StudyEvent: ODM
Description
Other Symptoms (Day 0-42)
Description
Medication
Description
Please fill in below if any medication has been taken since the vaccination
Data type
text
Description
Reason
Data type
text
Description
Total daily dose
Data type
text
Description
Start date
Data type
date
Description
End date
Data type
date
Description
Still taking medication?
Data type
boolean
Similar models
Diary Card: Unsolicited Symptoms (All Groups) - Dose 2
- StudyEvent: ODM
No comments